OTCMKTS:PVCT - Provectus Biopharmaceuticals Stock Price, News, & Analysis

$0.0609
+0.00 (+3.75 %)
(As of 06/25/2019 04:00 PM ET)
Today's Range
$0.0571
Now: $0.0609
$0.0620
50-Day Range
$0.0404
MA: $0.05
$0.06
52-Week Range
$0.0111
Now: $0.0609
$0.0780
Volume118,067 shs
Average Volume234,922 shs
Market Capitalization$23.44 million
P/E RatioN/A
Dividend YieldN/A
Beta0.61
Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PVCT
Previous SymbolNYSEMKT:PVCT
CUSIPN/A
Phone866-594-5999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.05) per share

Profitability

Net Income$-8,150,000.00

Miscellaneous

Employees2
Market Cap$23.44 million
Next Earnings Date8/6/2019 (Estimated)
OptionableNot Optionable

Receive PVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

When is Provectus Biopharmaceuticals' next earnings date?

Provectus Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Provectus Biopharmaceuticals.

Has Provectus Biopharmaceuticals been receiving favorable news coverage?

Headlines about PVCT stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Provectus Biopharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Provectus Biopharmaceuticals.

Who are some of Provectus Biopharmaceuticals' key competitors?

What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Cytori Therapeutics (CYTX), DARA Biosciences (DARA), Gilead Sciences (GILD), MaxLinear (MXL), Acacia Communications (ACIA), Biocept (BIOC), Caladrius Biosciences (CLBS) and Neuralstem (CUR).

Who are Provectus Biopharmaceuticals' key executives?

Provectus Biopharmaceuticals' management team includes the folowing people:
  • Dr. Timothy C. Scott, Pres (Age 61)
  • Dr. Eric A. Wachter, Co-Founder & Chief Technology Officer (Age 56)
  • Mr. Bruce Horowitz, Chief Operations Consultant & Director (Age 63)
  • Ms. Heather Raines, Chief Financial Officer (Age 52)

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Provectus Biopharmaceuticals' stock price today?

One share of PVCT stock can currently be purchased for approximately $0.0609.

How big of a company is Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals has a market capitalization of $23.44 million. Provectus Biopharmaceuticals employs 2 workers across the globe.View Additional Information About Provectus Biopharmaceuticals.

What is Provectus Biopharmaceuticals' official website?

The official website for Provectus Biopharmaceuticals is http://www.provectusbio.com/.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 866-594-5999 or via email at [email protected]


MarketBeat Community Rating for Provectus Biopharmaceuticals (OTCMKTS PVCT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  99
MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe PVCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PVCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2019 by MarketBeat.com Staff

Featured Article: What is Compound Interest?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel